01733nam a2200253   4500001000800000005001700008007000300025008004100028040000800069041000800077100003500085245004700120300002500167520098200192650001801174650002501192650002801217650003501245650001601280700002501296773011001321942003101431999001701462ESSALUD20260805002026.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aDu Toit, George eAutor953889  aPrevention and treatment of peanut allergy  apáginas: 2449-2458  aEarly introduction of peanut protein reduces allergy prevalence by approximately 80%, with efficacy diminishing as introduction is delayed. Appropriate prevention involves ingestion of approximately 2 g of peanut protein weekly for infants at low risk and 4 to 6 g weekly for infants at high risk. Population-level implementation that targets all infants achieves greater reduction in disease burden than approaches that target only high-risk groups, although disparities exist among some ethnic groups and groups with restricted access to care. Peanut immunotherapy initiated in younger children (1 to 3 years of age) shows superior efficacy and higher rates of clinical remission as compared with immunotherapy initiated in older children. The natural history of untreated peanut allergy follows a trajectory of increasing peanut-specific IgE levels and clinical reactivity over time, underscoring the importance of early intervention during this narrow developmental window.  aALERGIA97055  aDERMATOLOGÍA97479  aMEDICINA CLINICA933681  aENFERMEDADES INFANTILES953890  aNUTRICIÓN  aLack, Gideon 9538910 022717922639dMassachusetts NEJM GroupoNEJM006tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-07-31zSQB  c22764d22764